Nyxoah (NYXH) Q2 2026 earnings review
Record U.S. Adoption and a $110M Capital Injection Validate the Genio Threat
Nyxoah delivered a stellar Q2 2026, posting 21% sequential global revenue growth to €7.7 million, fueled heavily by the U.S. commercial rollout of its Genio sleep apnea system. Forward-looking indicators are flashing bright green: the U.S. patient prior-authorization pipeline exploded by 77% sequentially to 427 patients, and active clinical accounts doubled to 180. More importantly, management eliminated the dominant bear thesis—cash burn and runway—by securing a $110 million financing package. Cash now sits at an incredibly healthy €97.8 million, fully funding the aggressive U.S. commercial land-grab. While the back-half of the year requires a steep revenue ramp to meet the maintained €36-€40 million annual guidance, the surging patient pipeline makes this achievable.
🐂 Bull Case
The patient pipeline is converting rapidly. Patients entering Q3 under prior-authorization surged 77% to 427. Given Nyxoah's historical 100% PA approval rate, this directly forecasts a massive acceleration in Q3 and Q4 implants.
The $110M capital raise in Q2 pushed cash balances to €97.8M, completely removing the 'going concern' overhang from Q1 and providing a robust runway to achieve management's <€150M revenue break-even target.
🐻 Bear Case
To hit the midpoint of FY26 guidance (€38M), Nyxoah must generate €24M in H2, averaging €12M per quarter. If hospital Value Analysis Committees (VACs) slow down or surgical scheduling bottlenecks occur, they will miss.
Gross margin printed at 60%, down from 63% a year ago. The company cannot achieve the operating leverage needed for profitability until the Genio 2.2 disposable patch launches in early 2027.
⚖️ Verdict: 🟢
Bullish. The dual achievement of doubling active U.S. accounts and securing $110M in financing fundamentally changes the risk profile. The market adoption of Genio is accelerating exactly as planned, shifting the narrative from 'survival' to 'execution and scaling'.
Key Themes
U.S. Pipeline and Account Activation Hitting Escape Velocity
The commercial scaling metrics are outstanding. The company activated 89 new U.S. accounts in Q2, bringing the total to 180 (approaching half of their 400 high-volume target list). Surgeon training remains aggressive, with 55 new surgeons trained (262 total). Most importantly, the patient pipeline entering Q3 is 427—a massive 77% sequential jump from the 241 entering Q2. Because management maintains a 100% prior-authorization approval rate, this pipeline functions as a highly visible, de-risked forward revenue backlog.
Balance Sheet Fortified, Removing Key Overhang
Nyxoah ended Q1 with just €25.9M and a 'going concern' warning. Management successfully neutralized this in Q2 by securing $110M in aggregate financing, rocketing their cash and financial assets position to €97.8M. This allows them to fully fund the 40-person U.S. sales force and planned R&D expansions (Genio 2.2) without imminent dilution fears.
Favorable Macro Reimbursement Environment
The macro setup for Medicare and commercial coverage remains highly supportive. With a dedicated Medicare C-code (8011) now in place giving price parity with competitors, hospital adoption friction is minimized. Furthermore, CMS has proposed reimbursement increases of 12% for hospital outpatient and 15% for ambulatory surgical centers for 2027, which will heavily incentivize facilities to adopt Genio.
Gross Margin Stagnation Contradicts Scale Narrative
Despite U.S. revenue growing 22% sequentially and total global sales up 21%, gross margins remained stuck at 60% (down from 63% a year ago, heavily impacted by the higher mix of U.S. commercial infrastructure vs volume). This lack of near-term operating leverage on the COGS line is concerning. Meaningful expansion to the 70%+ target remains entirely gated by the launch of the Genio 2.2 low-cost disposable patch, which is not expected until early 2027. Scaling top-line without scaling product-level margins creates mid-term cash drag.
IP Litigation Overhead
The ongoing patent infringement lawsuit from Inspire Medical (initiated May 2025) and Nyxoah's subsequent counter-suit remains an unresolved overhang. While management previously stated this will not disrupt commercialization, legal expenses are mounting inside the SG&A line (€15.6M in Q2, up from €10.7M YoY) and will serve as a constant drain on cash until resolved.
Other KPIs
Net loss widened dramatically from €20.6 million a year ago, but the driver was mostly non-cash. While the operating loss was €20.6 million (reflecting U.S. commercial launch build-out), the company took a €13.1 million below-the-line financial expense. This was primarily driven by fair value mark-to-market adjustments on their convertible bonds and synthetic warrants, which fluctuate with equity value and volatility assumptions.
A transformative improvement from the €25.9M reported at the end of Q1 2026. This reflects the successful €110M in aggregate financing closed during Q2, which included an €81.1M equity raise and the drawdown of EIB loan tranches.
Accelerating. Up 46% YoY from €10.7M, reflecting the full weight of the expanded 40-person U.S. sales force and market access functions. By contrast, R&D expense actually declined YoY (€9.5M vs €10.1M) as clinical studies wind down and focus shifts entirely to commercial execution.
Guidance
Stable. The company maintained its full-year guidance. However, because H1 revenue was €14.0 million, the midpoint of this guidance (€38M) requires €24.0 million in the second half of the year. This implies a massive acceleration (over 70% half-over-half growth) that hinges heavily on converting the 427 patients in the prior-auth pipeline into immediate surgical implants.
Stable. Maintained expectations, implying Q3 and Q4 margins will tick up slightly from Q2's 60% and Q1's anomalous 57% to hit the midpoint.
Accelerating slightly. The guidance was raised by approximately €1.0 million (previously €98.0M midpoint) solely to account for one-time share-based compensation expense tied to the repricing of employee equity incentives in Q2.
Stable. Maintained expectations. Through H1 2026, cash OpEx is roughly €43.5 million, meaning the cash burn rate will remain flat to slightly elevated in H2, validating management's claim of disciplined financial management as revenue scales.
Key Questions
Patient Conversion Bottlenecks
With 427 patients in the prior-authorization pipeline, what is the current average lead time from PA approval to actually getting a patient into an operating room? Are you seeing any scheduling bottlenecks at high-volume centers?
Competitive Counter-Tactics
Now that you have activated 180 U.S. accounts, how is the incumbent competitor responding in those specific facilities? Are you seeing aggressive contracting or pricing adjustments to block Genio adoption?
Genio 2.2 Timeline Confidence
Given that the step-function improvement in gross margin to 70%+ is reliant on the Genio 2.2 low-cost disposable patch, what regulatory or manufacturing milestones remain to hit the early 2027 launch target?
Capitalizing on CMS Increases
CMS has proposed 12% to 15% rate increases for ASCs and outpatient facilities in 2027. How does your sales team leverage this data point in current hospital Value Analysis Committee (VAC) negotiations?